Table 4.
Novel immunosuppressive strategies
| Site of action | Agent | Human studies | ||
| Interruption of TCR/MHC | ||||
| binding | ||||
| CD4/MHC class II | Anti-CD4 mAbs | Yes | ||
| Interruption of T cell | ||||
| co-stimulation | ||||
| CD28/B7 | CTLA4-Ig | Yes (psoriasis) | ||
| CD40/CD154 | Anti-ICAM-1 mAbs | Yes (ITP) | ||
| Interruption of cell adhesion | ||||
| LFA-1/ICAM-1 | Anti-LFA-1 mAbs | Yes | ||
| Anti-ICAM-1 mAbs | Yes | |||
| Interruption of accessory | ||||
| molecule interactions | ||||
| CD2/LFA-3 | Anti-LFA-3 mAbs | No | ||
| Anti-CD2 mAbs | Yes | |||
| CD45 | Anti-CD45 | Yes |
ICAM-1, intracellular adhesion molecule-1; ITP, idiopathic thrombocytopenic purpura; LFA, lymphocyte function associated antigen; mAb, monoclonal antibody; MHC, major histocompatibility complex; TCR, T cell receptor.